SelectQuote, Inc. USDC – Southern District of New York august 20, 2025 CLASS PERIOD: september 9, 2020 – may 1, 2025LEAD PLAINTIFF DEADLINE: OCTOBER 10, 2025 Please complete the form below to contact Kaplan Fox regarding the SelectQuote, Inc. Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox Alerts Investors to a Securities Class Action Against SelectQuote, Inc. (SLQT) – Deadline is October 10, 2025 Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against SelectQuote, Inc. (“SelectQuote” or the “Company”) (NYSE: SLQT) on behalf of investors that purchased or otherwise acquired SelectQuote securities between September 9, 2020 and May 1, 2025 (the “Class Period”). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an investor in SelectQuote and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than October 10, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. On May 1, 2025, the U.S. Department of Justice (“DOJ”) filed a False Claims Act complaint against SelectQuote. The DOJ alleged that “[f]rom 2016 through at least 2021” some of the nation’s largest health insurance companies paid “tens of millions of dollars” in “illegal kickbacks” to SelectQuote and other insurance brokers in exchange for steering Medicare beneficiaries to enroll in the insurers’ plans. On this news, the price of SelectQuote stock fell $.61 per share, over 19%, to close at $2.56 per share. The class action complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose: (i) that the Company was directing Medicare beneficiaries to the plans offered by insurers that best compensated SelectQuote, regardless of the quality or suitability of the insurers’ plans; (ii) that SelectQuote did not provide unbiased comparison shopping for Medicare Advantage insurance plans; (iii) that SelectQuote received illegal kickbacks to steer Medicare beneficiaries to certain insurers and limit enrollment in competitors’ plans; (iv) that as a result, SelectQuote had not complied with applicable laws, regulations, and contractual provisions; and (v) that SelectQuote was vulnerable to regulatory and legal sanctions as a result of its conduct, including claims that it had violated the False Claims Act. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT: Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us SelectQuote, Inc. See the Case Unicycive Therapeutics, Inc. See the Case Fiserv, Inc. See the Case Simulations Plus, Inc. See the Case Inspire Medical Systems, Inc. See the Case Western Asset Management See the Case Hims & Hers Health, Inc. See the Case Fortrea Holdings, Inc. See the Case Abacus Global Management, Inc. See the Case Red Cat Holdings, Inc. See the Case Ibotta, Inc. See the Case Krispy Kreme, Inc. See the Case
